APN-PEG5-VC-PAB-MMAE is the drug-linker component of the INA03 antibody-drug conjugate, which targets CD71 (transferrin receptor 1). This cleavable conjugate enables the targeted delivery of the cytotoxic payload MMAE, facilitating research into novel ADC therapies in both in vitro and in vivo models for oncology.